Clinical Innovations is the maker of the ROM Plus, a rupture of membranes (ROM) diagnostic test, which provides immediate results to help minimize potential risks to expectant mothers and their babies. The device’s accuracy and ease of use provides a less invasive and more efficient alternative to traditional ROM detection methods used for more than 60 years, according to two new peer-reviewed clinical research papers recently published in Clinical Medicine Insights: Reproductive Health and Medical Devices: Evidence and Research.
Membrane rupture “can occur at any gestational age and presents a particularly serious clinical problem if it occurs prior to 37 weeks’ gestation, where it is responsible for [up to 40 percent] of preterm births,” according to new research from Clinical Medicine Insights: Reproductive Health. The ROM Plus’ point-of-care test uses a noninvasive approach to detect proteins found in significant concentrations in amniotic fluid.
Traditionally, other ROM tests can be invasive, requiring a speculum and microscope, which often produces inaccurate results and can expose mothers and babies to added risk. With 99 percent sensitivity, ROM Plus is an effective solution.
“Rupture of membranes is one of the most common diagnostic dilemmas in obstetrics, affecting up to 10 percent of pregnancies. By helping labor and delivery providers accurately detect ruptured membranes, ROM Plus can help identify or minimize potential complications.” said Dr. Ross McQuivey, chief medical officer for Clinical Innovations.
Clinical Innovations helps mothers and babies in more than 75 countries around the world. ROM Plus is a critical part of Clinical Innovations’ growing product portfolio, which includes the Koala Intrauterine Pressure Catheter and Kiwi Vacuum-Assisted Delivery System.
